Advertisement

Endokrine Hypertonie

  • Michael Stimpel

Zusammenfassung

Die endokrinen Hypertonieformen werden wie folgt eingeteilt:
  • Phäochromozytom,

  • Primärer Mineralokortikoidismus,

  • Primärer Aldosteronismus,

  • DOC-Tumoren,

  • Adrenogenitales Syndrom/Kongenitale adrenale Hyperplasie, Hyperkortisolismus: Cushing-Syndrom,

  • Primärer Hyperreninismus,

  • Akromegalie,

  • Hyperparathyreoidismus,

  • Endothelinproduzierende Tumoren,

  • Hypo- und Hyperthyreose.

Der Anteil der endokrinen Hypertonieformen an der sekundären Hypertonie beträgt etwa 15%; im Gesamtkollektiv der Hypertoniker findet sich somit eine Häufigkeit der endokrinen Hypertonie von etwa 0,1-0,2%.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

Phäochromozytom (Kapitel 14.1)

  1. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A, Boscaro M (1999) Risk factors and longterm follow-up of adrenal incidentalomas. J Clin Endocrinol Metab 84:520–526PubMedCrossRefGoogle Scholar
  2. Bravo EL (1996) Plasma or urinary metanephrines for the diagnosis of pheochromocytoma? This is the question. Ann Intern Med 125:331–332PubMedGoogle Scholar
  3. Cook DM, Loriaux L (1996) The incidental adrenal mass. Am J Med 101:88–94PubMedCrossRefGoogle Scholar
  4. Eisenhofer G, Keiser H, Friberg P, Mezey E, Huynh TT, Hiremagalur B, Ellingson T, Duddempudi S, Eijsbouts A, Lenders JWM (1998) Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 83:2175–2185PubMedCrossRefGoogle Scholar
  5. Eisenhofer G, Lenders JWM, Linehan WM, Walther MM, Goldstein DS, Keiser HR (1999) Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med 340: 1872–1879PubMedCrossRefGoogle Scholar
  6. Gifford RW, Manger WM, Bravo EL (1994) Pheochromocytoma. Endocrinol Metab Clin N Am 23:387–404Google Scholar
  7. Gross DJ, Avishai N, Meiner V, Filon D, Zbar B, Abeliovich D (1996) Familial pheochromocytoma associated with a novel mutation in the von Hippel-Lindau gene. J Clin Endocrinol Metab 81:147–149PubMedCrossRefGoogle Scholar
  8. Grossman E, Goldstein DS, Hoffman A, Keiser HR (1991) Glucagon and Clonidine testing in the diagnosis of pheochromocytoma. Hypertension 17:733–741PubMedCrossRefGoogle Scholar
  9. Hamada M, Shigematsu Y, Mukai M, Kazatani Y, Kokubu T, Hiwada K (1995) Blood pressure response to the valsalva maneuver in pheochromocytoma and pseudopheochromocytoma. Hypertension 25:266–271PubMedCrossRefGoogle Scholar
  10. Krane NK (1986) Clinically unsuspected pheochromocytomas. Experience at Henry Ford Hospital and a review of the literature. Arch Intern Med 146:54–57PubMedCrossRefGoogle Scholar
  11. Manelli M (1989) Diagnostic problems in pheochromocytoma. J Endocrinol Invest 12:739–757Google Scholar
  12. Manger WM, Gifford RW (1994) Phaeochromocytoma: a clinical overview. In: Swales JD (ed), Textbook of Hypertension, Blackwell Scientific Publications London, p 941–958Google Scholar
  13. Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ, Volk B, Kirste G (1993) Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med 329:1531–1538PubMedCrossRefGoogle Scholar
  14. Peaston RT, Lennard TWJ, Lai LC (1996) Overnight excretion of urinary catecholamines and metabolites in the detection of pheochromocytoma. J Clin Endocrinol Metab 81: 1378–1384PubMedCrossRefGoogle Scholar
  15. Reincke M, Allolio B (1995) Das Nebenniereninzidentalom. Dt Ärztebl 92:A-764-770Google Scholar
  16. Roelants V, Goulios C, Beckers C, Jamar F (1998) Iodine-131-MIBG scintigraphy in adults: interpretation revisited? J Nucl Med 39:1007–1012PubMedGoogle Scholar
  17. Schürmeyer TH, Engeroff B, von zur Mühlen A, Dralle H (1994) Symptomatik und endokrinologische Befunde bei katecholamin-sezernierenden Tumoren. Ergebnisse bei 106 konsekutiven Patienten. Dtsch Med Wschr 119:1721–1727PubMedCrossRefGoogle Scholar
  18. Scully RE, Mark EJ, McNeely BU (1986) Weekly clinicopathological exercises. Case 6-1986. N Engl J Med 314:431–439CrossRefGoogle Scholar
  19. Shapiro B, Copp JE, Sisson JC, Eyre PL, Wallis J, Beierwaltes WH (1985) 131-Iodine metaiodo-benzylguanidine for the locating of suspected pheochromocytoma. Experiences in 400 cases. J Nucl Med 26:576–585PubMedGoogle Scholar
  20. Stimpel M, Wambach G (1987) Diagnostik des Phäochromozytoms. Dtsch Med Wschr 112: 1422–1425PubMedCrossRefGoogle Scholar
  21. Stimpel M, Schürmeyer TH, Ivens K, Wambach G, Volkmann HP, von zur Mühlen A (1988) Diagnostische Bedeutung des Clonidin-Hemmtestes bei Phäochromozytom-Verdacht. Dtsch med Wschr 113:130–134PubMedCrossRefGoogle Scholar
  22. Stimpel M, Reiss U, Volkmann HP, Wambach G (1993) The overnight Clonidine suppression test (OCST) in the diagnosis of pheochromocytoma. Hypertension 21:131Google Scholar
  23. Tenebaum E, Lumbroso J, Schlumberger M et al (1995) Comparision of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma. J Nucl Med 36:1–6Google Scholar
  24. Vincent D, Pradalier A (1993) Pheochromocytoma-like catecholamine levels induced by clonidine cessation. Europ J Med 2:313Google Scholar
  25. Witteies RM, Kaplan EL, Roizen MF (2000) Sensitivity of diagnostic and functional tests for pheochromocytoma in clinical practice. Arch Intern Med 160:2521–2524CrossRefGoogle Scholar
  26. Young WF Jr (2000) Management approaches to adrenal incidentalomas. A view from Rochester, Minnesota. Endocrinol Metab Clin North Am 29:159–185PubMedCrossRefGoogle Scholar

Primärer Mineralokortikoidismus (Kapitel 14.2-14.5)

  1. Biglieri EG (1991) Spectrum of mineralocorticoid hypertension. Hypertension 17:251–261PubMedCrossRefGoogle Scholar
  2. Biglieri EG, Schambelan M (1979) The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism. J Clin Endocrinol Metab 49:87–91PubMedCrossRefGoogle Scholar
  3. Bornstein SR, Stratakis CA, Chrousos GP (1999) Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med 130:259–771Google Scholar
  4. Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textor SC, Gifford RW, Vidt DG (1983) The changing clinical spectrum of primary aldosteronism. Am J Med 74:641–651PubMedCrossRefGoogle Scholar
  5. Diederich S, Quinkler M, Hanke B, Bähr V, Oelkers W (1999) 11ß-Hydroxysteroid-Dehydrogenasen: Schlüssel-Enzyme der Mineralocorticoid-und Glucocorticoid-Wirkung. Dtsch med Wschr 124:51–55PubMedCrossRefGoogle Scholar
  6. Dluhy RG, Lifton RP (1999) Glucocorticoid-remediable aldosteronism. J Clin Endocrinol Metab 84:4341–4344PubMedCrossRefGoogle Scholar
  7. Edwards CRW (1998) Disorders of mineralocorticoid hormone secretion. In: Grossman A (ed) Clinical Endocrinology, Blackwell, Oxford 433–449Google Scholar
  8. Fallo F, Sonino N, Boscaro M, Armanini D, Mantero F, Dörr HG, Knorr D, Kuhnle U (1987) Dexamethasone-suppressible hyperaldosteronism: Pathophysiology, clinical aspects, and new insights into the pathogenesis. Klin Wochenschr 65:437–444PubMedCrossRefGoogle Scholar
  9. Fardella CE, Mosso L, Gomez-Sanchez C, Cortes P, Soto J, Gomez L, Pinto M, Huete A, Oestreicher E, Foradori A, Montero J (2000) Primary aldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85:1863–1867PubMedCrossRefGoogle Scholar
  10. Gross MD, Shapiro B (1989) Scintigraphic studies in adrenal hypertension. Semin Nucl Med 19:122–143PubMedCrossRefGoogle Scholar
  11. Irony I, Biglieri EG, Perloff D, Rubinoff H (1987) Pathophysiology of deoxycorticosterone-secreting drenal tumors. J Clin Endocrinol Metab 65:836–840PubMedCrossRefGoogle Scholar
  12. Jonsson JR, Klemm SA, Tunny TJ, Stowasser M, Gordon RD (1995) A new genetic test for familial hyperaldosteronism type 1 aids in the detection of curable hypertension. Biochem Biophys Res Commun 207:565–571PubMedCrossRefGoogle Scholar
  13. Kater CE, Biglieri EG (1994) Disorders of steroid 17alpha-hydroxylase deficiency. Endocrinol Metab Clin N Am 23:341–357Google Scholar
  14. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ullick S, Lalouel JM (1992) A chimaeric 11ß-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 355:262–265PubMedCrossRefGoogle Scholar
  15. Lifton RP, Dluhy RG, Powers M, Rich GM, Gutkin M, Fallo F, Gill JR, Feld L, Ganguly A, Laidlaw et al. (1992) Hereditary hypertension caused by chimaeric gene duplications and ectopic expression of aldosterone synthase. Nat Genet 2:66–74PubMedCrossRefGoogle Scholar
  16. Litchfield WR, New MI, Coolidge C, Lifton RP, Dluhly RG (1997) Evaluation of the dexa-methason suppression test for the diagnosis of glucocorticoid-remediable aldosteronism. J Clin Endocrin Metabol 82:3570–3573CrossRefGoogle Scholar
  17. Melby JC (1984) Primary aldosteronism. Kidney Int 26:769–778PubMedCrossRefGoogle Scholar
  18. Melby JC (1989) Clinical review 1: endocrine hypertension. J Clin Endocrin Metab 69: 697–704CrossRefGoogle Scholar
  19. Nocaudie-Calzada M, Huglo D, Lambert M, Ernst O, Proye C, Wemeau JL, Marchandise X (2000) Efficacy of iodine-131 6beta-methyl-iodo-19-norcholesterol scintigraphy and computed tomography in patients with primary aldosteronism. Eur J Nucí Med 26:1326–1332Google Scholar
  20. Stimpel M (1992) Diagnose des primären Aldosteronismus. Dtsch med Wschr 117:907–911PubMedCrossRefGoogle Scholar
  21. Stimpel M, Grimm U, Degenhardt S, Krone W, Wambach G (1992) Bedeutung des CaptoprilTests in der (Differential-) Diagnostik des primären Aldosteronismus. Nieren Hochdruckkrkht 21:582–584Google Scholar
  22. Stowasser M, Gordon RD (2000) Primary aldosteronism: learning from the study of familial varieties. J Hypertension 18:1165–1176CrossRefGoogle Scholar
  23. Weinberger MH, Fineberg NS (1993) The diagnosis of primary aldosteronism and separation of two major subtypes. Arch Intern Med 153:2125–2129PubMedCrossRefGoogle Scholar
  24. White PC, New MI, Dupont B (1987) Congenital adrenal hyperplasia (First of two parts). N Engl J Med 316:1519–1524PubMedCrossRefGoogle Scholar
  25. White PC, New MI, Dupont B (1987) Congenital adrenal hyperplasia (Second of two parts). N Engl J Med 316:1580–1586PubMedCrossRefGoogle Scholar
  26. White PC (1996) Inherited forms of mineralocorticoid hypertension. Hypertension 28:927–936PubMedCrossRefGoogle Scholar

Cushing-Syndrom (Kapitel 14.6)

  1. Arioglu E, Doppman J, Gomes M, Kleiner D, Mauro D, Barlow C, Papanicolaou DA (1998) Cushing’s syndrome caused by corticotropin sceretion by pulmonary tumorlets. N Engl J Med 339:883–886PubMedCrossRefGoogle Scholar
  2. Danese RD, Aron DC (1994) Cushing’s syndrome and hypertension. Endocrinol Metabol Clin N Am 23:299–324Google Scholar
  3. Doppman JL, Oldfield EH, Niemann LK (1998) Bilateral sampling of the internal jugular vein to distinguish between mechanisms of adrenocorticotropic hormone-dependent Cushing syndrome. Ann Intern Med 128:33–36PubMedGoogle Scholar
  4. Görges R, Knappe G, Gerl H, Ventz M, Stahl F (1999) Diagnosis of Cushing’s syndrome: reevaluation of midnight plasma Cortisol vs urinary free Cortisol and low-dose dexametha-sone suppression test in a large patient group. J Endocrinol Invest 22:241–249PubMedGoogle Scholar
  5. Gold PW, Loriaux DL, Roy A, Kling MA, Calabrese JR, Kellner CH, Nieman LK, Post RM, Pickar D, Galluci W, Avgerinos P, Paul S, Oldfield EH, Cutler GB, Chrousos GP (1986) Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing’s disease. Pathophysiologic and diagnostic implications. N Engl J Med 314:1329–1335PubMedCrossRefGoogle Scholar
  6. Graham KE, Samuels MH, Nesbit GM, Cook DM, O’Neill OR, Barnwell SL, Loriaux DL (1999) Cavernous sinus sampling is highly accurate in distinguishing Cushing’s disease from the ectopic adrenocorticotropin syndrome and in predicting intrapituitary tumor localization. J Clin Endocrinol Metab 84:1602–1610PubMedCrossRefGoogle Scholar
  7. Hermus ARMM, Pieters GFFM, Pesman GJ, Smals AGH, Benraad TJ, Kloppenborg PWC (1986) The corticotropin-releasing-hormone test versus the high-dose dexamethasone test in the differential diagnosis of Cushing’s syndrome. Lancet 2:540–544PubMedCrossRefGoogle Scholar
  8. Invitti C, Giraldi FP, De Martin M, Cavagnini F and The Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-Pituitary-Adrenal Axis (1999) Diagnosis and management of Cushing’s Syndrome: results of an Italian multicentre study. J Clin Endocrinol Metab 84:440–448PubMedCrossRefGoogle Scholar
  9. Kaltsas GA, Giannulis MG, Newell-price JDC, Dacie JE, Thakkar C, Afshar F, Monson JP, Grossman AB, Besser GM, Trainer PJ (1999) A critical analysis of the value of simultaneous inferior petrosal sampling in Cushing’s disease and the occult ectopic adrenocorticotropin syndrome. J Clin Endocrin Metab 84:487–492CrossRefGoogle Scholar
  10. Kaye TB, Crapo L (1990) The Cushing syndrome: an update on diagnostic tests. Ann Intern Med 112:434–444PubMedGoogle Scholar
  11. Leinung MC, Young WF, Whitaker MD, Scheithauer BW, Trastek VF, Kvols LK (1990) Diagnosis of corticotropin-producing bronchial carcinoid tumors causing Cushing’s syndrome. Mayo Clin Proc 65:1314–1321PubMedGoogle Scholar
  12. Liebl R (1986) Störfaktoren beim Dexamethason-Hemmtest. Klin Wochenschr 64:535–539PubMedCrossRefGoogle Scholar
  13. Müller J (1991) Sinnvolle und sinnlose Steroidbestimmungen: Zweckmäßige Labordiagnostik der Nebennierenfunktion. Schweiz med Wschr 121:482–487PubMedGoogle Scholar
  14. Newell-Price JDC, Trainer PJ, Besser GM, Grossman AB (1998) The diagnosis and differential diagnosis of Cushing’s syndrome and pseudo-Cushing’s states. Endocr Rev 19:647–672PubMedCrossRefGoogle Scholar
  15. Nieman LK, Chrousos GP, Oldfield EH, Avgerinos PC, Cutler GB Jr, Loriaux DL (1986) The ovine corticotropin-releasing hormone stimulation test and the dexamethasone test in the differential diagnosis of Cushing’s syndrome. Ann Intern Med 105:862–867PubMedGoogle Scholar
  16. Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, Cutler GB, Loriaux DL (1991) Petrosal sinus sampling with and without corticotropin-releasing hormone for the differental diagnosis of Cushing’s syndrome. N Engl J Med 325:897–905PubMedCrossRefGoogle Scholar
  17. Orth DN (1995) Cushing’s syndrome. N Engl J Med 332:791–803PubMedCrossRefGoogle Scholar
  18. Saruta T, Suzuki H, Handa M, Igarashi Y, Kondo K, Senba S (1986) Multiple factors contribute to the pathogenesis of hypertension in Cushing’s syndrome. J Clin Endocrin Metab 62:275–279CrossRefGoogle Scholar
  19. Shackleton CHL, Stewart PM (1990) The hypertension of apparent mineralocorticoid excess syndrome. In Biglieri EG, Melby JC (eds) Endocrine hypertension. Raven Press, New York S155–173Google Scholar
  20. Von Werder K (1998) Diagnostik von Krankheiten der Nebennierenrinde. Dtsch med Wschr 123:393–396CrossRefGoogle Scholar
  21. Yanovski JA, Cutler GB, Chrousos GP, Nieman LK (1999) The dexamethasone-suppressed corticotropin-releasing hormone Stimulation test differentiates mild Cushing’s disease from normal physiology. J Clin Endocrinol Metab 83:348–352CrossRefGoogle Scholar

Primärer Hyperreninismus (Kapitel 14.7)

  1. Corvol P, Pinet F, Galen FX, Plouin PF, Chatellier G, Pagny JY, Bruneval P, Camilleri JP, Menard J (1994) Primary reninism. In: Laragh JH, Brenner BM (eds) Hypertension. Pathophysiology, diagnosis, and management, 2nd ed. Raven Press, New YorkGoogle Scholar
  2. Baruch D, Corvol P, Alhenc-Gelas F, Dufloux MA, Guyenne TT, Gaux JC et al (1984) Diagnosis and treatment of renin-secreting tumors. Hypertension 6:760–766PubMedCrossRefGoogle Scholar
  3. Kreutz R, Zhou H, Pfeifer U, Gasc JM, Ganten D, Kessler FJ (1993) Primärer Hyperreninismus. Eine seltene Ursache der sekundären arteriellen Hypertonie. Dtsch med Wschr 118:1110–1114PubMedCrossRefGoogle Scholar

Akromegalie (Kapitel 14.8)

  1. Deray G, Rieu M, Devynck MA, Pernollet MG, Chanson P, Luton JP, Meyer P (1987) Evidence of an endogenous digitalis-like factor in the plasma of patients with acromegaly. N Engl J Med 316:575–580PubMedCrossRefGoogle Scholar
  2. Fallo F, Barzon L, Boscaro M, Casiglia E, Sonino N (1998) Effect of octreotide on 24-h blood pressure profile in acromegaly. Am J Hypertension 11:591–596CrossRefGoogle Scholar
  3. Freda PU, Wardlaw SL (1998) Editorial: primary medical therapy for acromegaly. J Clin Endocrinol Metab 83:3031–3033PubMedCrossRefGoogle Scholar
  4. López-Velasco R, Escobar-Morreale HF, Vega B, Villa E, Sancho JM, Moya-Mur JL, Garcia-Robles R (1997) Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension? J Clin Endocrinol Metab 82:1047–1053PubMedCrossRefGoogle Scholar
  5. Melmed S (1990) Acromegaly. N Engl J Med 322:966–977PubMedCrossRefGoogle Scholar
  6. Melmed S, Jackson I, Kleinberg D, Klibanski A (1998) Current treatment guidelines for acromegaly. J Clin Endocrinol Metab 83:2646–2652PubMedCrossRefGoogle Scholar

Primärer Hyperparathyreoidismus (Kapitel 14.9)

  1. Diamond TW, Botha JR, Wing J, Meyers AM, Kalk WJ (1986) Parathyroid hypertension. A reversible disorder. Arch Intern Med 146:1709–1712PubMedCrossRefGoogle Scholar
  2. Lewanczuk RZ, Pang PK (1993) Expression of parathyroid factor in hypertensive primary hyperparathyroid patients. Blood Pressure 2:22–27PubMedCrossRefGoogle Scholar

Endothelinproduzierende Tumoren (Kapitel 14.10)

  1. Yokokawa K, Tahara H, Kohno M, Murakawa K, Yasunari K, Nakagawa K, Hamada T, Otani S, Yanagisawa M, Takeda T (1991) Hypertension associated with endothelin-secreting malignant hemangioendothelioma. Ann Intern Med 114:213–215PubMedGoogle Scholar

Hypo-und Hyperthyreoidismus (Kapitel 14.11)

  1. Saito I, Ito K, Saruto T (1983) Hypothyroidism as a cause of hypertension. Hypertension 5:112–115PubMedCrossRefGoogle Scholar
  2. Saito I, Saruto T (1994) Hypertension in thyroid disorders. Endocrinol Metab Clin N Am 23:379–386Google Scholar
  3. Streeten DH, Anderson GH, Howland T, Chang R, Smulyan H (1988) Effects of thyroid function on blood pressure. Recognition of hypothyroid hypertension. Hypertension 11:78–83PubMedCrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2001

Authors and Affiliations

  • Michael Stimpel
    • 1
  1. 1.Reha Klinik GmbH DampDampGermany

Personalised recommendations